MCE MedChemExpress

Product Data Sheet

(+)-Kavain

Cat. No.: HY-B1671
CAS No.: 500-64-1
Molecular Formula: $C_{14}H_{14}O_3$
Molecular Weight: 230.26

Target: GABA Receptor; Sodium Channel; Calcium Channel

Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling

Storage: 4°C, sealed storage, away from moisture and light

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (217.15 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	4.3429 mL	21.7146 mL	43.4292 mL
	5 mM	0.8686 mL	4.3429 mL	8.6858 mL
	10 mM	0.4343 mL	2.1715 mL	4.3429 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (9.03 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: \geq 2.08 mg/mL (9.03 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (9.03 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	(+)-Kavain, a main kavalactone extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na ⁺ and Ca ²⁺ channels ^[1] . (+)-Kavain is shown to bind at the α 4 β 2 δ GABA _A receptor and potentiate GABA efficacy ^[2] . (+)-Kavain is used as a treatment for inflammatory diseases, its anti-inflammatory action has been widely studied ^[4] .
IC ₅₀ & Target	Na $^+$, Ca $^{2+}$ channel $^{[1]}$. $\alpha 4\beta 2\delta$ GABA $_A$ receptor $^{[2]}$.

In Vitro

(+)-Kavain (10-300 μ M) enhances GABA-elicited responses in a concentration-dependent manner. The modulatory effect of Kavain is moderate, with only 170±23% of enhancement measured at 300 μ M^[2]. (+)-Kavain inhibits TNF- α secretion in cells via suppression of LITAF^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Bradić I, et al. [Hirschsprung's disease -- therapy and results]. Acta Chir Iugosl. 1975;22(2):183-95.
- [2]. Chua HC, et al. Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism. PLoS One. 2016 Jun 22;11(6):e0157700.
- [3]. G. Boonen, et al. In vivo Effects of the Kavapyrones (+)-Dihydromethysticin and (±)-Kavain on Dopamine, 3,4-Dihydroxyphenylacetic Acid, Serotonin and 5-Hydroxyindoleacetic Acid Levels in Striatal and Cortical Brain Regions. Planta Medica 64 (1998) 507-510.
- [4]. Tang X, et al. Kavain Inhibition of LPS-Induced TNF-α via ERK/LITAF. Toxicol Res (Camb). 2016 Jan 1;5(1):188-196.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA